CMLF — Stock Film
STOCK FILMSCENE 1/9CMLF · $11.60
Stock Expert AI presents
CMLF
CM Life Sciences, Inc
~4 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
CM Life Sciences, Inc. What it actually does.

Identify potential private companies for acquisition. Conduct due diligence on target companies. Now — the numbers.

on the stock market since 2020
WHERE DOES THE MONEY COME FROM?
49%Diagnostic Test
Diagnostic TestDiagnostic Test, Third Party Insurance 41%Diagnostic Test, Institutional Customers 8%Product and Service, Other 1%Diagnostic Test, Self Pay <1%
49% of all revenue comes from a single line: Diagnostic Test.

The biggest line carries real weight, but it doesn’t decide everything on its own.

Revenue last year:
$427.5M
The loss that same year:
$21M
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$171.3M
DEBT: $60.5M
At this pace, that money lasts about 8.1 years.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
A strong cash pile8/10
WEAK SPOTS
The stock has lost its spark0/10
1
THE BRIGHT SIDE · 1/3
The product is selling

Sales run at $427.5M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/3
Strong cash, light debt

There is $171.3M in the vault; even if every debt were paid off, $110.8M would remain.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 3 buys and 1 sell. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small scale, thin loss

A loss of $21.0M against $427.5M in annual sales.

2
THE RISKS · 2/2
The stock has lost its spark

Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.

FINALE · THE GRADE
grade pending

We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.

One-line summary: few numbers, an untested story. Keep watching.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the price history.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film